Research study looking for people who have survived cancer against the odds

Velindre Cancer Service has launched the Rosalind Study in Wales, an international research initiative aimed at understanding the unique characteristics of people who beat the odds to survive aggressive cancer. 

Led by French techbio company Cure51, the Rosalind study seeks to uncover the biological factors that contribute to exceptional, long-term survival in cancer patients and unlock insights that could pave the way for more effective cancer treatment. It is being led at Velindre by Dr Sahar Iqbal, Consultant Clinical Oncologist, Velindre Cancer Service.

Three specific cancer types

The study focuses on individuals who have defied the odds by surviving either extensive stage small cell lung cancer or metastatic pancreatic ductal adenocarcinoma for more than five years from diagnosis, or brain cancer glioblastoma for more than three years.

Eligible patients will simply need to give their consent to use their data and tumour samples already held by Velindre. The samples will be sent to Cure51 to undertake analysis.

If you think you may be eligible and would like to help unlock insights that could pave the way for more effective cancer treatment, please email Velindre Cancer Service at Rosalind.study@wales.nhs.uk .